Patent Face-Off: FDA Denial Isn’t The End Of Rapid-Exchange Dispute
This article was originally published in The Gray Sheet
Executive Summary
FDA has denied a citizen petition seeking to derail Abbott's efforts to extend its rapid-exchange delivery patent for the Xience V drug-eluting stent, but the petitioner says that was all according to plan
You may also be interested in...
Rapid Exchange In Cardiac Cath Space: Medtronic Launches, Abbott Sues
Medtronic finally reentered the U.S. market with popular rapid-exchange (RX) coronary catheter delivery systems Oct. 30 after an eight-year absence, prompting an immediate patent infringement suit from Abbott
Medtronic, AngioScore Challenge Abbott’s Attempt To Extend Catheter Patent
Device firms Medtronic and AngioScore are fighting an effort by Abbott to extend the life of its valuable "rapid-exchange" catheter patent, set to expire Oct. 29
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.